000			02311 a2200565 4500
005			20250515235029.0
264		0	_c20110614
008			201106s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdq408 _2doi
040			_aNLM _beng _cNLM
100	1		_aScholz, M
245	0	0	_aImpact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cMar 2011
300			_a681-688 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAlgorithms
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBleomycin _xadverse effects
650	0	4	_aCyclophosphamide _xadverse effects
650	0	4	_aDacarbazine _xadverse effects
650	0	4	_aDoxorubicin _xadverse effects
650	0	4	_aEtoposide _xadverse effects
650	0	4	_aGlyoxal _xadverse effects
650	0	4	_aHodgkin Disease _xdrug therapy
650	0	4	_aHumans
650	0	4	_aIfosfamide _xadverse effects
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLeukemia, Myeloid, Acute _xchemically induced
650	0	4	_aLymphoma, Non-Hodgkin _xchemically induced
650	0	4	_aMyelodysplastic Syndromes _xchemically induced
650	0	4	_aNeoplasms, Second Primary _xchemically induced
650	0	4	_aPrednimustine _xadverse effects
650	0	4	_aPrednisone _xadverse effects
650	0	4	_aProcarbazine _xadverse effects
650	0	4	_aProportional Hazards Models
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRisk Assessment
650	0	4	_aTreatment Outcome
650	0	4	_aVinblastine _xadverse effects
650	0	4	_aVincristine _xadverse effects
700	1		_aEngert, A
700	1		_aFranklin, J
700	1		_aJosting, A
700	1		_aDiehl, V
700	1		_aHasenclever, D
700	1		_aLoeffler, M
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 22 _gno. 3 _gp. 681-688
856	4	0	_uhttps://doi.org/10.1093/annonc/mdq408 _zAvailable from publisher's website
999			_c20056072 _d20056072